EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men

Joel M Palefsky iD, Anna R Giuliano, Stephen E Goldstone, Brady Dubin, Alfred Saah, Alain Luxembourg, Christine Velicer, Joseph E Tota

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf584 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Joel M Palefsky und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Homosexuality, Male, Anus Diseases. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Critical gaps exist in our understanding of the progression from anal human papillomavirus (HPV) infection to same-type HPV-associated anal disease in HIV-negative men who have sex with men (MSM). We conduced a post hoc analysis of a phase 3 randomized 4-valent HPV vaccine trial (NCT00090285) to assess the natural progression of anal HPV infections to associated anal lesions among MSM.

Participants

602 HIV-negative MSM aged 16–27 years.

Methods

HIV-negative MSM aged 16–27 years enrolled in the placebo arm from 18 countries were included. We estimated distribution of 9-valent HPV (9vHPV) vaccine types in intra-anal lesions (anal condyloma and anal intraepithelial neoplasia [AIN] 1–3), proportions and rates of progression from incident-persistent (no associated anal disease at baseline) intra-anal HPV infections to a same-type HPV-associated anal lesion, and cumulative incidence over 30 months.

Results

Predominant 9vHPV types detected were HPV6 (55.7%) and HPV11 (25.3%) in MSM with anal condyloma/AIN1, and HPV6 (30.5%), HPV16 (22.0%), and HPV11 (15.3%) in those with pooled AIN2/3. Progression from incident-persistent intra-anal 9vHPV infection to anal disease was driven primarily by HPV6, HPV11, and HPV16/18 infections for MSM with anal condyloma/AIN1 (63.0%, 85.7%, and 16.3%, respectively) and AIN2/3 (25.9%, 14.3%, and 32.4%, respectively). Cumulative incidence of anal condyloma/AIN1 and AIN2/3 in MSM with incident-persistent infection were 43.1% and 34.4%, respectively.

Conclusion

A high proportion of unvaccinated HIV-negative MSM with a new intra-anal 9vHPV infection, developed same-type HPV-associated anal disease. These findings support HPV vaccination of young HIV-negative MSM to prevent anal HPV infection and associated anal disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsHomosexuality, MaleAnus DiseasesHumansMaleAdultYoung AdultAdolescentDisease ProgressionPapillomavirus VaccinesPapillomaviridaeAnus NeoplasmsIncidenceAnal CanalSexual and Gender Minorities

Stichwörter der Autor:innen

HPV infectionHPV vaccinesanal condylomaanal intraepithelial neoplasiahuman papillomavirus

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Center for Immunization and Infection Research in Cancer (CIIRC), Moffitt Cancer Center, Tampa, Florida, USA.
  • Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Global Medical and Scientific Affairs, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Vaccine Clinical Development, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Joel M Palefsky

Förderung

  • Merck Sharp & Dohme LLC
  • Merck & Co., Inc.

Zitieren

APA

Palefsky, J. M., Giuliano, A. R., Goldstone, S. E., Dubin, B., Saah, A., Luxembourg, A., Velicer, C., & Tota, J. E. (2025). Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf584

Vancouver

Palefsky JM, Giuliano AR, Goldstone SE, Dubin B, Saah A, Luxembourg A, et al. Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf584

BibTeX
@article{Palefsky2025,
  author = {Palefsky, Joel M and Giuliano, Anna R and Goldstone, Stephen E and Dubin, Brady and Saah, Alfred and Luxembourg, Alain and Velicer, Christine and Tota, Joseph E},
  title = {Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf584}
}
Kostenlos starten →